Hostname: page-component-6766d58669-l4t7p Total loading time: 0 Render date: 2026-05-19T03:55:59.571Z Has data issue: false hasContentIssue false

Immunoglobulin G4 related chronic sclerosing sialadenitis

Published online by Cambridge University Press:  23 March 2015

E L Culver
Affiliation:
Translational Gastroenterology Unit, John Radcliffe Hospital and Oxford University, Oxford, UK
A Hunt
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, John Radcliffe Hospital, Oxford, UK
E Crewe
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, John Radcliffe Hospital, Oxford, UK
K A Shah
Affiliation:
Department of Cellular Pathology, John Radcliffe Hospital, Oxford, UK
P Martinez-Devesa*
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, John Radcliffe Hospital, Oxford, UK
*
Address for correspondence: Mr Pablo Martinez-Devesa, Department of Otorhinolaryngology – Head and Neck Surgery, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK Fax: 01865 231 091, E-mail: Pablo.Martinez-Devesa@ouh.nhs.uk

Abstract

Background:

ENT surgeons may be the first specialists to encounter and diagnose patients with salivary gland disease. A new entity involving the salivary glands has recently been described of which ENT surgeons need to be aware: immunoglobulin G4 related chronic sclerosing sialadenitis.

Method:

A literature search of Medline, Embase and Cochrane Library databases was performed, using the search terms ‘IgG4’, ‘hyperIgG4 syndrome’ and ‘IgG4 related chronic sclerosing sialadenitis’.

Results:

Knowledge concerning immunoglobulin G4 related chronic sclerosing sialadenitis is rapidly increasing. This new entity is part of a fibro-inflammatory corticosteroid-responsive systemic disease (immunoglobulin G4 related disease) and has been described in almost every organ. Biopsy of the submandibular gland can be diagnostic. However, the diagnosis can easily be overlooked if: clinical suspicion is not high, one is unaware of the classical morphology and/or immunoglobulin G4 staining is not performed. This paper presents a summary of the current understanding of the disease and its management.

Conclusion:

ENT surgeons should be aware of this new disease entity. Patients with systemic disease should be managed under a multidisciplinary team, with input from clinicians who have an interest in such diseases (such as gastroenterologists and rheumatologists), and input from histopathologists and radiologists.

Information

Type
Review Articles
Copyright
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable